Review
doi: 10.1007/s00259-004-1571-4.
Epub 2004 May 19.
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours
Affiliations
- PMID: 15150675
- DOI: 10.1007/s00259-004-1571-4
Item in Clipboard
Review
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours
Eur J Nucl Med Mol Imaging.
2004 Jul.
Abstract
Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue (90)Y-[DOTA](0)-Tyr(3)-octreotide [(90)Y-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.
Similar articles
-
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.Eur J Nucl Med Mol Imaging. 2004 Oct;31(10):1386-92. doi: 10.1007/s00259-004-1561-6. Epub 2004 Jun 3. Eur J Nucl Med Mol Imaging. 2004. PMID: 15175836 Clinical Trial.
-
[Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].Praxis (Bern 1994). 1999 Aug 15;88(31-32):1263-8. Praxis (Bern 1994). 1999. PMID: 10479965 German.
-
Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?Med Sci Monit. 2002 Apr;8(4):LE7. Med Sci Monit. 2002. PMID: 11951054 No abstract available.
-
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.Semin Nucl Med. 2002 Apr;32(2):133-40. doi: 10.1053/snuc.2002.31027. Semin Nucl Med. 2002. PMID: 11965608 Review.
-
Experience with indium-111 and yttrium-90-labeled somatostatin analogs.Curr Pharm Des. 2002;8(20):1781-807. doi: 10.2174/1381612023393756. Curr Pharm Des. 2002. PMID: 12171531 Review.
Cited by
-
Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease.J Endocrinol Invest. 2008 Apr;31(4):352-9. doi: 10.1007/BF03346370. J Endocrinol Invest. 2008. PMID: 18475055
-
A phase one, single-dose, open-label, clinical safety and PET/MR imaging study of 68Ga-DOTATOC in healthy volunteers.Am J Nucl Med Mol Imaging. 2017 Apr 15;7(2):53-62. eCollection 2017. Am J Nucl Med Mol Imaging. 2017. PMID: 28533937 Free PMC article.
-
Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review.Pituitary. 2008;11(1):93-102. doi: 10.1007/s11102-007-0038-6. Pituitary. 2008. PMID: 17458701 Review.
-
Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1407-16. doi: 10.1007/s00259-009-1115-z. Epub 2009 Mar 25. Eur J Nucl Med Mol Imaging. 2009. PMID: 19319527 Clinical Trial.
-
Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning.Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2426-2441. doi: 10.1007/s00259-018-4044-x. Epub 2018 May 21. Eur J Nucl Med Mol Imaging. 2018. PMID: 29785514 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
